By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
Bristol-Myers Squibb (BMY) Release: Modern Family Star Eric Stonestreet Challenges Americans To Support The Cancer Community And Learn About Immuno-Oncology Research Through Ready. Raise. Rise. 6/28/2017 6:29:33 AM
What Makes Biogen (BIIB) and Bristol-Myers Squibb (BMY) Such Attractive Takeover Targets 6/27/2017 6:32:40 AM
Bristol-Myers Squibb (BMY) Release: Four-Year Follow-Up With Empliciti (Elotuzumab) Plus Lenalidomide/Dexamethasone (Eld) In Patients With Advanced Multiple Myeloma Shows Long-Term Efficacy In ELOQUENT-2 Trial 6/26/2017 6:09:22 AM
Ocular Therapeutix (OCUL) Names Bristol-Myers Squibb (BMY)-Novartis AG (NVS) Vet As New CEO 6/23/2017 7:19:04 AM
Bristol-Myers Squibb (BMY) Announces The Pricing Terms Of Its Cash Tender Offer For Any And All Of Certain Of Its Outstanding Debt Securities 6/21/2017 6:59:58 AM
Bristol-Myers Squibb (BMY) Announces The Expiration Of Its Cash Tender Offer 6/21/2017 6:36:38 AM
Bristol-Myers Squibb (BMY) Release: Extended Follow-Up Data Evaluating Opdivo (Nivolumab) Shows Durable Response In Adult Patients With Relapsed Or Progressed Classical Hodgkin Lymphoma 6/16/2017 6:45:00 AM
Is The Market Wrong About Bristol-Myers Squibb (BMY)? 6/16/2017 5:49:46 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Seattle Genetics (SGEN) And Bristol-Myers Squibb (BMY) Highlight Interim Phase I/II Data Evaluating Combination Of ADCETRIS (Brentuximab Vedotin) And Opdivo (Nivolumab) In Relapsed Hodgkin Lymphoma At The International Conference On Malignant Lymphoma 6/15/2017 6:43:21 AM
12345678910...
//-->